Journal: Gels

Article Title: Enzyme Responsive Vaginal Microbicide Gels Containing Maraviroc and Tenofovir Microspheres Designed for Acid Phosphatase-Triggered Release for Pre-Exposure Prophylaxis of HIV-1: A Comparative Analysis of a Bigel and Thermosensitive Gel

doi: 10.3390/gels8010015

Figure Lengend Snippet: Cytotoxic effect of the varying concentrations of maraviroc and tenofovir microspheres, negative and positive control on the HeLa cell lines. Results are given as mean ± SD, n = 3.

Article Snippet: Cell lines: HeLa cells and fetal bovine serum were purchased from Cell Lines Service GmbH, Germany.

Techniques: Positive Control

Journal: Nature Communications

Article Title: Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin

doi: 10.1038/s41467-023-42714-4

Figure Lengend Snippet: a Activity of 3033 on JAK family enzymes. Human HEL 92.1.7 cells were treated with siRNA at 1.5 μM for 72 h, and mRNA levels of JAK1, JAK2, JAK3, and TYK2 were measured using the QuantiGene 2.0 assay ( n = 7 biologically independent samples, mean ± s.d.; one-way ANOVA, **** P < 0.0001, ns: not significant). b Ruxolitinib inhibits JAK1 and JAK2 to prevent the pathogenesis of vitiligo driven by IFN-γ signaling. c mRNA expression of IFN-γ-inducible chemokines CXCL9, 10, and 11. Cells were first treated with siRNA or ruxolitinib at 1.5 μM for 72 h, and then stimulated with recombinant human IFN-γ for 24 h ( n = 7 biologically independent samples, mean ± s.d.; one-way ANOVA, ** P < 0.01, **** P < 0.0001). d , e Chemical engineering of 3033 for skin delivery. Terminal nucleotides were stabilized with phosphorothioate backbone modifications for nuclease stability ( d ). Human HeLa cells were transfected with DCA-siRNAs for 72 h through lipofectamine RNAiMax-mediated uptake and mRNA levels were measured using the QuantiGene 2.0 assay ( n = 3 biologically independent samples, mean ± s.d.; two-way ANOVA multiple comparison, * P < 0.05). f Molecular modeling (PyMOL 2) of DCA-siRNA 3033 in scaffold 2, si3033. g – i ruxolitinib and si3033 both reduce luciferase activity in IFN-γ-JAK1/2-STAT1 HeLa reporter cells ( n = 7 biologically independent samples, mean ± s.d.; one-way ANOVA, ** P < 0.01, **** P < 0.0001). Cells were treated with ruxolitinib or siRNA for 72 h and then stimulated with IFN-γ for 18 h. si3033 was transfected to the HeLa reporter cells using lipofectamine RNAiMax. j JAK1 and JAK2 mRNA expression in si3033-treated and untreated HeLa reporter cells ( n = 7 biologically independent samples, mean ± s.d.; two-sided unpaired t test, **** P < 0.0001, ns: not significant). Source data are provided as a Source Data file.

Article Snippet: GAS reporter (Luc)-HeLa cell line (IFN-γ/JAK/STAT1 pathway) was purchased from BPS Bioscience (#79041).

Techniques: Activity Assay, Expressing, Recombinant, Transfection, Comparison, Luciferase

Journal: Frontiers in Oncology

Article Title: A tumor cell specific Zona Pellucida glycoprotein 3 RNA transcript encodes an intracellular cancer antigen

doi: 10.3389/fonc.2023.1233039

Figure Lengend Snippet: ZP3-Cancer is the dominant transcript in tumor cells and is differentially distributed among cancer types. (A) Expression of the seven annotated ZP3 transcripts in CCls (n=1339). Bars represent Tukey box plots (boxes are median+IQR). Median transcript expression levels (from left to right) are 2.47, 0.22, 0.0, 0.04, 0.42, 0.0 and 0.0 TPM. ZP3-Cancer expression is significantly higher compared to all other transcripts (Kruskal-Wallis test, p < 0.0001). NC = Non-protein coding. (B) Relative expression of ZP3-cancer and ZP3-Oocyte in the CCLs MCF7 and HeLa, and in healthy ovarian tissue containing follicles, as determined by qPCR. ZP3-Cancer expression is set to 1 for MCF7 and HeLa, ZP3-Oocyte expression is set to 1 for ovarian tissue. ‘ZP3-both’ served as a positive control and used primers designed to detect ZP3-Cancer and ZP3-Oocyte simultaneously. Bars represent mean+SD for the triplicate qPCR reactions. (C) Differential expression of ZP3-Cancer in the cancer types covered by the CCLs. Cancer types represented by less than 5 CCLs were not included. Bars represent Tukey box plots (boxes are median+IQR). Number of samples are indicated between brackets. The shaded area indicates CCLs with a ZP3-Cancer expression level below the overall median (2.54 TPM).

Article Snippet: Total RNA extracted from the breast cancer cell line MCF7 (R1255830-50) and the cervical cancer cell line HeLa (R1255811-50) was purchased from Amsbio (Abingdon, UK).

Techniques: Expressing, Positive Control